Abstract
Recombinant human growth hormone, a very potent anabolic hormone, plays a significant role in growth regulation, bone metabolism, and wound healing. This study evaluates its effect on random flap survival. Rats were randomly divided into 2 groups. A dorsal random flap, cephalically based, was used. One group received 5 mg/kg subcutaneous injection of recombinant human growth hormone 1 hour before surgery and a repeat dosage every 24 hours for 1 week. The others served as controls. At the end of 1 week, average weight and flap survival was evaluated. There was no difference in flap survival between the groups. Treated rats had gained significantly more weight. Recombinant human growth hormone had no beneficial effect on flap survival. The lack of a deleterious effect of the hormone on random flap survival and its significant effect on rat weight and well being supports its safe use during flap surgery.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
